Search
Revolution Medicines Inc
RVMDAdd to Watchlist
189.260USD
-4.260-2.20%
Close 10-15 16:00（ET）
40.24BMarket Cap
LossP/E TTM
Revolution Medicines Inc (RVMD) Stock Price Target & Forecast
Analyst Rating
Based on 24 analysts giving stock ratings to Revolution Medicines Inc in the past month.
Buy
9 Strong Buy
14 Buy
1 Hold
0 Sell
0 Strong Sell
Target Price
259.784USD+37.86%
RVMD Analyst Recommendation Trends
In the current month, RVMD has received 14 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. RVMD average Analyst price target in the last month is 259.784.
2026-10
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
9
8
8
9
9
9
9
9
14
14
13
13
12
12
12
12
1
1
1
1
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
24
23
22
23
21
21
21
21
RVMD Analyst Rating for Peer Comparison
Updated: Oct 15, 2026Company name
Strong Buy
Buy
Hold
Sell
Strong Sell
Analysts
Beigene Ltd
ONC
8
19
0
0
0
27
argenx SE
ARGX
10
14
3
0
0
27
Insmed Inc
INSM
7
18
0
0
0
25
Ionis Pharmaceuticals Inc
IONS
6
14
5
0
0
25
Kymera Therapeutics Inc
KYMR
9
13
2
0
0
24
IQVIA Holdings Inc
IQV
8
12
3
0
0
23
Tempus AI Inc
TEM
4
7
11
0
1
23
Biontech SE
BNTX
4
12
7
0
0
23
Ascendis Pharma A/S
ASND
9
13
0
0
0
22
Cytokinetics Inc
CYTK
4
16
2
0
0
22
Financial Forecasting
Based on analysts' estimates, RVMD EPS is projected to reach -2.411 in FY2026Q3, following reported EPS of -3.055 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-1.58
-1.84
-1.98
-2.41
-2.06
Actual
-1.88
-2.29
-3.06
--
--
Surprise
-18.66%
-24.56%
-54.49%
--
--
FAQs
What is Revolution Medicines Inc's expected revenue for the next quarter?
Revolution Medicines Inc's expected revenue is 2.42M.
What is Revolution Medicines Inc's price target?
Analysts forecast that Revolution Medicines Inc's price target is USD 259.78, with the highest forecast at USD 320.00 and the lowest forecast at USD 179.00.
How have Revolution Medicines IncRVMD's recent earnings per share performed?
The market expectation was USD -3.06, while Revolution Medicines IncRVMD's earnings per share (EPS) for the previous quarter was USD -2.29. EPS for the next quarter is expected at USD -2.41.
What is the analyst rating for Revolution Medicines Inc?
Based on the ratings of Revolution Medicines Inc's stock from 24 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.